Procter & Gamble Health has informed that at the meeting of the Board of Directors of the Company held today (commenced at 12.45 pm and ended at 2:55 pm), the Audited Financial Results for Financial Year ended June 30, 2022 were approved. The company has enclosed the following: Audited Financial Results for the Financial Year ended June 30, 2022, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, Auditor’s Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company, Press Release and A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results. Further, the Board of Directors of the Company at its meeting held today, have recommended a final dividend of Rs 11.50 per equity share, for the financial year ended June 30, 2022. The dividend shall be paid between November 28, 2022 to December 18, 2022, on approval of the Members at the 55th Annual General Meeting.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |